ArticleRadiation oncology journal2026
Prognostic significance of the neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma treated with proton beam therapy.
Article in Radiation oncology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluated the impact of neutrophil-to-lymphocyte ratio on the survival of patients with esophageal squamous cell carcinoma (ESCC) who underwent proton beam therapy with concurrent chemotherapy. MATERIALS AND
methodsData of patients with ESCC who received definitive proton beam therapy with concurrent chemotherapy between January 2015 and January 2020 were retrospectively analysed. The 3-year overall and progression-free survival rates were calculated. Prognostic factors, including neutrophil-to-lymphocyte ratio, were examined.
resultsIn total, 116 consecutive patients with ESCC (median age, 68 years; range, 45 to 90 years) were included. The median follow-up time was 51.2 months (range, 3.0 to 114.0). Complete clinical response was observed in 75 patients (64.7%). The 3-year overall and progression-free survival rates were 82.4% and 59.4%, respectively. In a multivariate analysis, a Eastern Cooperative Oncology Group performance status ≥1 (hazard ratio [HR], 2.52; 95% confidence interval [CI], 1.00 to 6.34; p = 0.049), clinical stage Ⅳ disease according to the Union for International Cancer Control 8th edition (HR, 3.37; 95% CI, 1.30 to 8.77; p = 0.013), and a neutrophil-to-lymphocyte ratio ≥3.00 (HR, 3.89; 95% CI, 1.36 to 11.19; p = 0.012) were significantly associated with poorer overall survival. Clinical stage Ⅳ disease (HR, 2.86; 95% CI, 1.50 to 5.44; p = 0.003) and neutrophil-to-lymphocyte ratio ≥3.00 (HR, 2.40; 95% CI, 1.32 to 4.39; p = 0.004) were significantly associated with poorer progression-free survival.
conclusionIn patients with ESCC who received definitive proton beam therapy with concurrent chemotherapy, a high neutrophil-to-lymphocyte ratio was a significant poor prognostic factor for both overall and progression-free survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.